Lithuania
2012: National Dementia Strategies (diagnosis, treatment and research)
Issues relating to medical treatment
The availability of medicines in general
Medicines in Lithuania are fully covered for children under 18, persons with group 1 disability and for hospital treatment. 50% of the price of medicines is covered for old-age pensioners, persons with group 2 disability and other persons entitled to a social insurance protection[1].
The Lithuanian system prescribes reimbursement levels for medicines for specific diseases on a special list for which reimbursement can be 50%, 80%, 90% or 100% depending on the disease.
Conditions surrounding the prescription and reimbursement of AD drugs
In Lithuania, only donepezil and memantine are part of the reimbursement system. People with an MMSE score between 20 and 0 can qualify for the reimbursement of donepezil. There are no restrictions in Lithuania for the reimbursement of these treatments for people living alone or in nursing homes.
| Prescription and reimbursement | Rivastigmine | Galantamine | Memantine |
|
| Available | Yes | No | No | Yes |
| Reimbursed | Yes | N/A | N/A | Yes |
| Required examinations | MMSE | N/A | N/A |
|
| MMSE limits | 20-0 | N/A | N/A |
|
Issues relating to research
Lithuania is not involved in the EU Joint Programme – Neurodegenerative Disease Research (JPND) but is an Associate member of the Joint Action “Alzheimer Cooperative Valuation in Europe (ALCOVE)”.
[1] European Commission (2011): MISSOC – Mutual information system on social protection : Social protection in the Member States of the European Union, of the European Economic Area and in Switzerland: Comparative tables
Last Updated: Tuesday 14 May 2013
